Human papillomavirus type 16 E5 protein induces expression of beta interferon through interferon regulatory factor 1 in human keratinocytes

Journal of Virology

Volumn 85, Issue 10, 2011, Pages 5070-5080

  Muto, Valentina ^a   Stellacci, Emilia ^b   Lamberti, Angelo Giuseppe ^a   Perrotti, Edvige ^b   Carrabba, Aurora ^a   Matera, Giovanni ^a   Sgarbanti, Marco ^b   Battistini, Angela ^b   Liberto, Maria Carla ^a   Focá, Alfredo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CASPASE 8; DOUBLE STRANDED RNA DEPENDENT PROTEIN KINASE R; INTERFERON REGULATORY FACTOR 1; PROTEIN E6; PROTEIN KINASE R; UNCLASSIFIED DRUG;

ARTICLE; BETA INTERFERON GENE; CARCINOGENESIS; CONTROLLED STUDY; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; INTERFERON INDUCTION; INTERFERON STIMULATED GENE; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

CELL LINE; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON-BETA; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 79955445198     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02114-10     Document Type: Article

References (57)

1. Ablasser, A., et al. 2009. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat. Immunol. 10:1065-1072.
2. Alazawi, W., et al. 2002. Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Res. 62: 6959-6965.
3. Barbaresi, S., et al. 2010. Effects of human papillomavirus type 16 E5 deletion mutants on epithelial morphology: functional characterization of each transmembrane domain. J. Gen. Virol. 91:521-530.
4. Barnard, P., and N. A. McMillan. 1999. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 259: 305-313.
5. Battistini, A. 2009. Interferon regulatory factors in hematopoietic cell differentiation and immune regulation. J. Interferon Cytokine Res. 29:765-780.
6. Bouvard, V., G. Matlashewski, Z. M. Gu, A. Storey, and L. Banks. 1994. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology 203:73-80.
7. Castle, P. E., and A. R. Giuliano. 2003. Genital tract infections, cervical inflammation, and antioxidant nutrients: assessing their roles as human papillomavirus cofactors. J. Natl. Cancer Inst. Monogr. 2003:29-34.
8. Chang, Y. E., and L. A. Laimins. 2000. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 74:4174-4182.
9. Chang, Y. E., L. Pena, G. C. Sen, J. K. Park, and L. A. Laimins. 2002. Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J. Virol. 76:8864-8874.
10. Ciccaglione, A. R., et al. 2007. Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes. J. Virol. 81:202-214.
11. Crusius, K., E. Auvinen, B. Steuer, H. Gaissert, and A. Alonso. 1998. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp. Cell Res. 241:76-83.
12. Fehrmann, F., D. J. Klumpp, and L. A. Laimins. 2003. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J. Virol. 77:2819-2831.
13. Fragale, A., et al. 2008. IFN regulatory factor-1 negatively regulates CD4+ CD25+ regulatory T cell differentiation by repressing Foxp3 expression. J. Immunol. 181:1673-1682.
14. Fulda, S. 2009. Caspase-8 in cancer biology and therapy. Cancer Lett. 281: 128-133.
15. Ganguly, N., and S. P. Parihar. 2009. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J. Biosci. 34:113-123.
16. Garcia, M. A., et al. 2006. Impact of protein kinase R in cell biology: from antiviral to antiproliferative action. Microbiol. Mol. Biol. Rev. 70:1032-1060.
17. Garnett, T. O., and P. J. Duerksen-Hughes. 2006. Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. Arch. Virol. 151:2321-2335.
18. Genther, S. M., et al. 2003. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J. Virol. 77:2832-2842.
19. Gerein, V., E. Rastorguev, J. Gerein, P. Jecker, and H. Pfister. 2005. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann. Otol. Rhinol. Laryngol. 114:463-471.
20. Harada, H., et al. 1989. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58:729-739.
21. Herdman, M. T., et al. 2006. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 27:2341-2353.
22. Honda, K., A. Takaoka, and T. Taniguchi. 2006. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25:349-360.
23. Jeon, S., B. L. Allen-Hoffmann, and P. F. Lambert. 1995. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69:2989-2997.
24. Kim, K. Y., L. Blatt, and M. W. Taylor. 2000. The effects of interferon on the expression of human papillomavirus oncogenes. J. Gen. Virol. 81:695-700.
25. Kim, S. H., S. Gunnery, J. K. Choe, and M. B. Mathews. 2002. Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. Oncogene 21:8741-8748.
26. Kim, S. H., et al. 2006. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1,2 and PI3K/Akt. Cell. Mol. Life Sci. 63:930-938.
27. Kim, S. H., et al. 2009. Involvement of NF-KB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 30:753-757.
28. Kroger, A., M. Koster, K. Schroeder, H. Hauser, and P. P. Mueller. 2002. Activities of IRF-1. J. Interferon Cytokine Res. 22:5-14.
29. Lin, R., A. Mustafa, H. Nguyen, D. Gewert, and J. Hiscott. 1994. Mutational analysis of interferon (IFN) regulatory factors 1 and 2. Effects on the induction of IFN-beta gene expression. J. Biol. Chem. 269:17542-17549.
30. Lohoff, M., et al. 1997. Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity 6:681-689.
31. Maelfait, J., and R. Beyaert. 2008. Non-apoptotic functions of caspase-8. Biochem. Pharmacol. 76:1365-1373.
32. McCoy, C. E., S. Carpenter, E. M. Palsson-McDermott, L. J. Gearing, and L. A. O'Neill. 2008. Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation. J. Biol. Chem. 283:14277-14285.
33. Munger, K., et al. 2004. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78:11451-11460.
34. Nees, M., et al. 2000. Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. Cancer Res. 60:4289-4298.
35. Oelze, I., J. Kartenbeck, K. Crusius, and A. Alonso. 1995. Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line. J. Virol. 69:4489-4494.
36. Park, J. S., et al. 2000. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem. 275:6764-6769.
37. Pett, M. R., et al. 2006. Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc. Natl. Acad. Sci. U. S. A. 103:3822-3827.
38. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
39. γ signalling pathways through synergistic induction of IRF-1/ISGF-2 is mediated by a composite GAS/κB promoter element. Nucleic Acids Res. 25:4346-4354.
40. Regan, J. A., and L. A. Laimins. 2008. Bap31 is a novel target of the human papillomavirus E5 protein. J. Virol. 82:10042-10051.
41. Remoli, A. L., et al. 2006. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem. J. 396:371-380.
42. Ronco, L. V., A. Y. Karpova, M. Vidal, and P. M. Howley. 1998. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12:2061-2072.
43. Ruiz-Ruiz, C, et al. 2004. The up-regulation of human caspase-8 by inter-feron-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J. Biol. Chem. 279:19712-19720.
44. Sgarbanti, M., et al. 2002. Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors. J. Exp. Med. 195:1359-1370.
45. Sgarbanti, M., et al. 2004. Analysis of the signal transduction pathway leading to human immunodeficiency virus-1-induced interferon regulatory factor-1 upregulation. Ann. N. Y. Acad. Sci. 1030:187-195.
46. Sgarbanti, M., et al. 2008. IRF-1 is required for full NF-κB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer. J. Virol. 82:3632-3641.
47. Shirasawa, H., Y. Tomita, S. Sekiya, H. Takamizawa, and B. Simizu. 1987. Integration and transcription of human papillomavirus type 16 and 18 sequences in cell lines derived from cervical carcinomas. J. Gen. Virol. 68:583-591.
48. Stanley, M. A., H. M. Browne, M. Appleby, and A. C. Minson. 1989. Properties of a non-tumorigenic human cervical keratinocyte cell line. Int. J. Cancer 43:672-676.
49. Stetson, D. B., and R. Medzhitov. 2006. Type I interferons in host defense. Immunity 25:373-381.
50. Stoler, M. H., et al. 1992. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol. 23:117-128.
51. Stoppler, M. C, S. W. Straight, G. Tsao, R. Schlegel, and D. J. McCance. 1996. The E5 gene of HPV-16 enhances keratinocyte immortalization by full-length DNA. Virology 223:251-254.
52. Straight, S. W., P. M. Hinkle, R. J. Jewers, and D. J. McCance. 1993. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J. Virol. 67:4521-4532.
53. Takahashi, K., et al. 2006. Roles of caspase-8 and caspase-10 in innate immune responses to double-stranded RNA. J. Immunol. 176:4520-4524.
54. Taniguchi, T., K. Ogasawara, A. Takaoka, and N. Tanaka. 2001. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19:623-655.
55. Tomakidi, P., H. Cheng, A. Kohl, G. Komposch, and A. Alonso. 2000. Modulation of the epidermal growth factor receptor by the human papillomavirus type 16 E5 protein in raft cultures of human keratinocytes. Eur. J. Cell Biol. 79:407-412.
56. Valle, G. F., and L. Banks. 1995. The human papillomavirus (HPV)-6 and HPV-16 E5 proteins operate with HPV-16 E7 in the transformation of primary rodent cells. J. Gen. Virol. 76:1239-1245.
57. Woodman, C. B., S. I. Collins, and L. S. Young. 2007. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer 7:11-22.